[Bone marrow aplasia associated to the use of ticlopidine].
We report a 58 years old male that developed a bone marrow aplasia associated to the use of ticlopidine, prescribed after coronary artery stenting. The patient developed a pneumonia as a complication. He was admitted to the Intermediate Treatment Unit, receiving wide spectrum antimicrobial therapy and a granulocyte colony stimulating factor (Neupogen(r)) with favourable response. Ticlodipine is an effective antiplatelet agent, but has serious hematological and other side effects. Its prescription requires a close follow up and search for complications.